Department of Speech Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Department of Radiation Therapy Services, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Pract Radiat Oncol. 2013 Oct-Dec;3(4):e187-94. doi: 10.1016/j.prro.2012.11.009. Epub 2013 Jan 3.
This study used prospective swallowing data to establish the following: (1) whether doses to the pharyngeal constrictor muscles (PCMs) were significantly associated with swallowing outcomes; and (2) a mean dose constraint to aim for in intensity modulated radiation therapy planning.
The PCMs were contoured and radiation dose data obtained for 55 patients with head and neck cancer. Associations between radiation dose and percentage of pharyngeal residue, penetration-aspiration and activity limitation measured at 6 months posttreatment were analyzed. Pretreatment swallowing function, tumor site, T classification, and chemotherapy were accounted for in multivariate analyses.
On multivariate analysis, the percentage of pharyngeal residue was statistically significantly associated with the mean dose to the superior PCM (95% confidence interval [CI], 0.15-1.66; P = .02). Penetration-aspiration was associated with the mean dose to the superior, middle, and inferior PCMs (95% CI, 1.02-1.27; P = .003; 95% CI, 1.02-1.23; P = .003; 95% CI, 1.04-1.21; P = .003, respectively) and the mean dose to the total PCM (95% CI, 1.05-1.31; P = .001). Activity limitation was also associated with the mean dose to the superior, middle, and inferior PCMs (95% CI, 1.01-1.20; P = .02; 95% CI, 1.00-1.15; P =.04; 95% CI, 1.01-1.15; P = .02, respectively) and the mean dose to the total PCM (95% CI, 1.02-1.23; P = .01). On univariate analysis, all 3 swallowing measures were statistically significantly worse for patients who received a biologically equivalent mean dose of >60 Gy to the PCMs. This remained significant on multivariate analysis for both penetration-aspiration and activity limitation (95% CI, 2.05-58.2, P = .004 and 95% CI, 1.14-27.7, P = .03, respectively).
The radiation dose to the PCMs is significantly associated with swallowing dysfunction. Limiting the mean PCM dose to less than 60 Gy results in better swallowing outcomes.
本研究使用前瞻性吞咽数据来确定以下内容:(1)咽缩肌(PCM)的剂量是否与吞咽结果显著相关;(2)在调强放疗计划中,为实现的平均剂量约束。
对 55 例头颈部癌症患者进行 PCM 勾画和辐射剂量数据采集。分析治疗后 6 个月时,咽后残留量、渗透-吸入和活动受限与辐射剂量之间的关系。在多变量分析中考虑了预处理吞咽功能、肿瘤部位、T 分类和化疗。
多变量分析显示,咽后残留量与上 PCM 的平均剂量呈统计学显著相关(95%置信区间[CI],0.15-1.66;P =.02)。渗透-吸入与上、中、下 PCM 的平均剂量(95%CI,1.02-1.27;P =.003;95%CI,1.02-1.23;P =.003;95%CI,1.04-1.21;P =.003)和总 PCM 的平均剂量(95%CI,1.05-1.31;P =.001)相关。活动受限也与上、中、下 PCM 的平均剂量(95%CI,1.01-1.20;P =.02;95%CI,1.00-1.15;P =.04;95%CI,1.01-1.15;P =.02)和总 PCM 的平均剂量(95%CI,1.02-1.23;P =.01)相关。单变量分析显示,所有 3 项吞咽测量结果在接受 PCM 等效生物剂量>60Gy 的患者中均明显更差。多变量分析显示,渗透-吸入和活动受限仍然具有统计学意义(95%CI,2.05-58.2,P =.004 和 95%CI,1.14-27.7,P =.03)。
PCM 的辐射剂量与吞咽功能障碍显著相关。将 PCM 的平均剂量限制在 60Gy 以下可获得更好的吞咽结果。